Guardant Health, Inc. (NASDAQ:GH) Director Myrtle S. Potter Sells 2,626 Shares

Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Myrtle S. Potter sold 2,626 shares of Guardant Health stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $49.70, for a total transaction of $130,512.20. Following the completion of the sale, the director now owns 18,180 shares in the company, valued at approximately $903,546. This trade represents a 12.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Guardant Health Trading Up 2.1%

GH stock traded up $1.04 during trading on Thursday, reaching $50.57. 2,844,143 shares of the stock were exchanged, compared to its average volume of 2,136,298. The firm has a market capitalization of $6.27 billion, a price-to-earnings ratio of -14.92 and a beta of 1.37. The business has a 50 day moving average price of $44.16 and a 200-day moving average price of $41.86. Guardant Health, Inc. has a 1 year low of $20.14 and a 1 year high of $52.92.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.08. Guardant Health had a negative net margin of 53.82% and a negative return on equity of 1,200.44%. The business had revenue of $203.47 million during the quarter, compared to the consensus estimate of $189.91 million. During the same quarter last year, the firm earned ($0.46) EPS. The business's revenue was up 20.8% compared to the same quarter last year. On average, research analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on GH. Raymond James Financial reissued an "outperform" rating and set a $59.00 target price (up previously from $39.00) on shares of Guardant Health in a report on Friday, February 21st. Stephens reissued an "overweight" rating and issued a $55.00 price objective on shares of Guardant Health in a research note on Wednesday, March 26th. The Goldman Sachs Group raised their price objective on Guardant Health from $49.00 to $56.00 and gave the company a "buy" rating in a report on Friday, February 21st. TD Securities lifted their target price on shares of Guardant Health from $56.00 to $60.00 and gave the stock a "buy" rating in a research note on Thursday, May 1st. Finally, JPMorgan Chase & Co. upped their target price on shares of Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. Twenty-one analysts have rated the stock with a buy rating, According to data from MarketBeat, Guardant Health currently has a consensus rating of "Buy" and a consensus price target of $53.76.

Institutional Investors Weigh In On Guardant Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Osterweis Capital Management Inc. purchased a new position in Guardant Health during the first quarter worth about $12,634,000. Rhumbline Advisers raised its stake in shares of Guardant Health by 4.9% in the 1st quarter. Rhumbline Advisers now owns 175,432 shares of the company's stock valued at $7,473,000 after acquiring an additional 8,202 shares during the period. Strs Ohio acquired a new position in shares of Guardant Health in the 1st quarter worth approximately $809,000. Intech Investment Management LLC lifted its holdings in shares of Guardant Health by 37.3% in the 1st quarter. Intech Investment Management LLC now owns 60,187 shares of the company's stock worth $2,564,000 after acquiring an additional 16,363 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Guardant Health by 6.3% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,777,040 shares of the company's stock worth $118,302,000 after purchasing an additional 164,263 shares during the period. Institutional investors and hedge funds own 92.60% of the company's stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.